Overview

  • Product nameAnti-C3 antibody
    See all C3 primary antibodies
  • Description
    Goat polyclonal to C3
  • SpecificityBy immunoelectrophoresis and ELISA this antibody reacts specifically with Dog C3. ab112829 may cross react with C3 from other species.
  • Tested applicationsSuitable for: WB, ELISA, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Dog
  • Immunogen

    Whole normal dog serum

Properties

Applications

Our Abpromise guarantee covers the use of ab112829 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/30000. Predicted molecular weight: 187 kDa. Colorimetric: Use 1/1000 - 1/10000; Chemiluminescent: Use 1/1000 - 1/30000.
ELISA 1/500 - 1/30000. Coating: Use 1/100 - 1/500; Primary: Use 1/1000 - 1/30000.
ICC/IF 1/200 - 1/2000.
IHC-P 1/200 - 1/2000.

Target

  • FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similaritiesContains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational
    modifications
    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Alternative names
    • Acylation stimulating protein cleavage product antibody
    • AHUS5 antibody
    • ARMD9 antibody
    • ASP antibody
    • C3 and PZP like alpha 2 macroglobulin domain containing protein 1 antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • CO3_HUMAN antibody
    • Complement C3 antibody
    • Complement C3c alpha'' chain fragment 2 antibody
    • Complement component 3 antibody
    • Complement factor 3 antibody
    • CPAMD1 antibody
    • HEL S 62p antibody
    see all

References for Anti-C3 antibody (ab112829)

ab112829 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab112829.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"